Safusidenib (AB-218, DS-1001)
G307
Nuvation Bio · Phase 3 · Not yet recruiting · Enrollment 140
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
Safusidenib (AB-218, DS-1001)
Nuvation Bio · Phase 3 · Not yet recruiting · Enrollment 140
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.